207 related articles for article (PubMed ID: 17121789)
1. Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy.
Petre CE; Sin SH; Dittmer DP
J Virol; 2007 Feb; 81(4):1912-22. PubMed ID: 17121789
[TBL] [Abstract][Full Text] [Related]
2. Kaposi's Sarcoma-Associated Herpesvirus MicroRNAs Target GADD45B To Protect Infected Cells from Cell Cycle Arrest and Apoptosis.
Liu X; Happel C; Ziegelbauer JM
J Virol; 2017 Feb; 91(3):. PubMed ID: 27852859
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.
Sarek G; Kurki S; Enbäck J; Iotzova G; Haas J; Laakkonen P; Laiho M; Ojala PM
J Clin Invest; 2007 Apr; 117(4):1019-28. PubMed ID: 17364023
[TBL] [Abstract][Full Text] [Related]
4. Recruitment of the tumour suppressor protein p73 by Kaposi's Sarcoma Herpesvirus latent nuclear antigen contributes to the survival of primary effusion lymphoma cells.
Santag S; Jäger W; Karsten CB; Kati S; Pietrek M; Steinemann D; Sarek G; Ojala PM; Schulz TF
Oncogene; 2013 Aug; 32(32):3676-85. PubMed ID: 22964633
[TBL] [Abstract][Full Text] [Related]
5. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53.
Rivas C; Thlick AE; Parravicini C; Moore PS; Chang Y
J Virol; 2001 Jan; 75(1):429-38. PubMed ID: 11119611
[TBL] [Abstract][Full Text] [Related]
6. Kaposi's sarcoma herpesvirus lytic replication compromises apoptotic response to p53 reactivation in virus-induced lymphomas.
Sarek G; Ma L; Enbäck J; Järviluoma A; Moreau P; Haas J; Gessain A; Koskinen PJ; Laakkonen P; Ojala PM
Oncogene; 2013 Feb; 32(9):1091-8. PubMed ID: 22469985
[TBL] [Abstract][Full Text] [Related]
7. A Screen for Extracellular Signal-Regulated Kinase-Primed Glycogen Synthase Kinase 3 Substrates Identifies the p53 Inhibitor iASPP.
Woodard C; Liao G; Goodwin CR; Hu J; Xie Z; Dos Reis TF; Newman R; Rho H; Qian J; Zhu H; Hayward SD
J Virol; 2015 Sep; 89(18):9232-41. PubMed ID: 26109723
[TBL] [Abstract][Full Text] [Related]
8. Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma.
Carbone A; Gloghini A; Vaccher E; Cerri M; Gaidano G; Dalla-Favera R; Tirelli U
J Mol Diagn; 2005 Feb; 7(1):17-27. PubMed ID: 15681470
[TBL] [Abstract][Full Text] [Related]
9. Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas.
Chen W; Hilton IB; Staudt MR; Burd CE; Dittmer DP
J Virol; 2010 Apr; 84(8):3898-908. PubMed ID: 20130056
[TBL] [Abstract][Full Text] [Related]
10. Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
Bhatt S; Ashlock BM; Toomey NL; Diaz LA; Mesri EA; Lossos IS; Ramos JC
J Clin Invest; 2013 Jun; 123(6):2616-28. PubMed ID: 23635777
[TBL] [Abstract][Full Text] [Related]
11. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
12. Spindle cell conversion by Kaposi's sarcoma-associated herpesvirus: formation of colonies and plaques with mixed lytic and latent gene expression in infected primary dermal microvascular endothelial cell cultures.
Ciufo DM; Cannon JS; Poole LJ; Wu FY; Murray P; Ambinder RF; Hayward GS
J Virol; 2001 Jun; 75(12):5614-26. PubMed ID: 11356969
[TBL] [Abstract][Full Text] [Related]
13. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.
Parravicini C; Chandran B; Corbellino M; Berti E; Paulli M; Moore PS; Chang Y
Am J Pathol; 2000 Mar; 156(3):743-9. PubMed ID: 10702388
[TBL] [Abstract][Full Text] [Related]
14. p53 inhibition by the LANA protein of KSHV protects against cell death.
Friborg J; Kong W; Hottiger MO; Nabel GJ
Nature; 1999 Dec 23-30; 402(6764):889-94. PubMed ID: 10622254
[TBL] [Abstract][Full Text] [Related]
15. p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas.
Sarek G; Ojala PM
Cell Cycle; 2007 Sep; 6(18):2205-9. PubMed ID: 17890905
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of p53 function in synovial sarcoma cells by inhibition of p53-HDM2 interaction.
D'Arcy P; Ryan BA; Brodin B
Cancer Lett; 2009 Mar; 275(2):285-92. PubMed ID: 19081178
[TBL] [Abstract][Full Text] [Related]
17. Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells.
Ye F; Lattif AA; Xie J; Weinberg A; Gao S
Cell Cycle; 2012 Apr; 11(7):1393-9. PubMed ID: 22421142
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility of KSHV-Infected PEL Cell Lines to the Human Complement System.
Yoo SM; Jeon H; Lee S; Lee MS
J Microbiol Biotechnol; 2016 Mar; 26(3):618-26. PubMed ID: 26699745
[TBL] [Abstract][Full Text] [Related]
19. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway.
Lee HR; Toth Z; Shin YC; Lee JS; Chang H; Gu W; Oh TK; Kim MH; Jung JU
J Virol; 2009 Jul; 83(13):6739-47. PubMed ID: 19369353
[TBL] [Abstract][Full Text] [Related]
20. Sangivamycin induces apoptosis by suppressing Erk signaling in primary effusion lymphoma cells.
Wakao K; Watanabe T; Takadama T; Ui S; Shigemi Z; Kagawa H; Higashi C; Ohga R; Taira T; Fujimuro M
Biochem Biophys Res Commun; 2014 Feb; 444(2):135-40. PubMed ID: 24434142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
